Press Room

bonus 1a

Press Releases 2021

Analysis of results obtained from a phase II, multi-center clinical trial in severe Covid-19 patients treated with Bonus BioGroup's drug product MesenCure, showed that; MesenCure treatment resulted in a survival rate of 94% of the severe patients treated and reduced their hospitalization period by about half Bonus BioGroup (TASE: BONS)…
A patent approval secures Bonus BioGroup protection for the exclusivity of use and commercialization in Europe, in addition to the US, of Engineered Nanoparticle Technology, which may enable the development of a variety of therapies for the acceleration of the repair of injured tissue or tissue loss Bonus BioGroup (TASE:…
Moshe Bar Siman Tov,former CEO of the Israeli Ministry of Health, joins the Business Advisory Board of Bonus BioGroup Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus BioGroup is pleased to announce the addition of…
Following the approval by the Israeli Ministry of Health for additional medical centers to join in phase II clinical trial for the treatment of severe Covid-19 with Bonus BioGroup's drug product MesenCureBonus BioGroup is preparing to adjust its manufacturing capacity for an increase in severe Covid-19 patients - leased a…
As Covid-19 infections are rising and in light of significant improvements in the health and recovery of severe Covid-19 patients treated with MesenCure;The Israeli Ministry of Health approved the joining of additional medical centers to the Phase II clinical trial for severe Covid-19 evaluating Bonus BioGroup's product MesenCure Bonus BioGroup…
In view of the spread of new variants of coronavirus, reduced vaccine effectiveness, and the imminent rise in Covid-19 incidence;Bonus BioGroup demonstrated significant improvement in parameters indicating reduced tissue damage, including muscle tissue, in addition to alleviating pneumonia in severe Covid-19 patients treated with the advanced cell therapy product MesenCure…
At the International Society for Cell & Gene Therapy (ISCT) 2021 annual meeting in New Orleans,Bonus BioGroup presented complete success in treating COVID-19 patients with MesenCure, which significantly improved the patients’ healthThe Israel Ministry of Health approved the phase II clinical trial for the treatment of life-threatening respiratory distress with…
Bonus BioGroup developed a network of artificial blood vessels, intended to enable better integration of transplanted lab-grown organsA US granted patent provides Bonus BioGroup with exclusive rights for the development and marketing of its network of artificial blood vessels, which may become an essential component in tissue engineering Bonus BioGroup…
Following safety and efficacy preclinical results of the unique drug product MesenCure, a therapy specifically developed by Bonus BioGroup for the life-threatening acute respiratory distress in coronavirus (Covid-19) patients and pneumonia; Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and…

INFORMATION FOR INVESTORS  |  CAREER OPPORTUNITIES  |  INFORMATION FOR PATIENTS   |   RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

INFORMATION FOR INVESTORS

CAREER OPPORTUNITIES

INFORMATION FOR PATIENTS

RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

MAIL ICON  info@bonus-bio.com

MAIL ICON  +972 (0)73 206 7104

MAIL ICONMatam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel

you tube linkedin facebook twitter

© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd

Please publish modules in offcanvas position.